Many studies examining and comparing the effects of disease-modifying therapies in MS were presented over the three days of the ECTRIMS 2018 conference in Berlin. Here are summaries of just some of the research presented:
- The sphingosine 1-phosphate receptor (S1PR) modulator ozanimod was found to significantly reduce the rate of relapse, including severe relapse, compared with interferon beta-1a in patients with relapsing MS. The finding followed analysis of pooled data from two phase III studies, involving 2,659 patients. (Comi G, et al. P869)
Vous souhaitez en lire plus ?
Connectez-vous à votre compte ou inscrivez-vous à Neurodiem pour consulter la suite.
Vous avez déjà un compte ? S'identifier
Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.